

**UnitedHealthcare Community Plan of Ohio Clinical
Pharmacy Program Guideline Changes**

UnitedHealthcare Community Plan’s Clinical Pharmacy Program Guidelines are updated on an ongoing basis by our Pharmacy and Therapeutics Committee. Our changes reflect recent developments in pharmaceutical health care so we’re aligned with national treatment standards. The following summary outlines our most recent updates.

New Guidelines

Guideline Name	Eff. Date	Comments
Trelegy Ellipta	July 1, 2018	New program

Guideline Modifications

Guideline Name	Eff. Date	Comments
Azole Antifungals	July 1, 2018	Minor updates throughout the policy to align with most recent IDSA updates. Added IDSA off-label uses section.
GLP-1 Agonists	July 1, 2018	Added Bydureon BCise and Ozempic to policy. Removed from policy due to manufacturer discontinuation in July 2018.
HIV	July 1, 2018	Added Juluca to policy
Ibrance	July 1, 2018	Minor language/formatting change to Breast Cancer section. Added NCCN Recommended Regimen review criteria.
Insulins	July 1, 2018	Added Admelog vial/Solostar and Fiasp products to the policy. Moved open access insulin table to background. Updated preferred products. Added review criteria for Admelog Solostar.
Kisqali	July 1, 2018	Added step therapy criteria through trial of both Verzenio and Ibrance or allow continuation of Kisqali therapy. Added NCCN Recommended review criteria.
Mepron	July 1, 2018	Revised language around step therapy medications.
Nityr	July 1, 2018	Removed all criteria except diagnosis since Nityr will become part of Diagnosis to Drug Match
Orfadin	July 1, 2018	Added step through Nityr for initial authorization. Added reauthorization review criteria.
Progesterone-Oral	July 1, 2018	Added history of preterm birth and prevention of preterm delivery for current pregnancy as approvable conditions.
SGLT-2 Inhibitors	July 1, 2018	Added Steglatro and Segluromet to the policy. Updated preferred and non-preferred products.
Verzenio	July 1, 2018	Added criteria for additional indication. Added NCCN Recommended Regimen review criteria.

If you have any questions regarding this summary, please call Provider Services at **800-600-9007**. Thank you.